Photo from wikipedia
Polypharmacy is common in the hemodialysis population and increases the likelihood that patients will be exposed to clinically significant drug–drug interactions. Concurrent use of proton pump inhibitors (PPIs) with citalopram… Click to show full abstract
Polypharmacy is common in the hemodialysis population and increases the likelihood that patients will be exposed to clinically significant drug–drug interactions. Concurrent use of proton pump inhibitors (PPIs) with citalopram or escitalopram may potentiate the QT‐prolonging effects of these selective serotonin reuptake inhibitors through pharmacodynamic and/or pharmacokinetic interactions.
Keywords:
proton pump;
citalopram escitalopram;
hemodialysis;
pump inhibitors
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!